Torasemid: the pathway in the body
This page shows the biochemical pathway of the active substance Torasemid: where it arrives in the body, where it acts and which steps are affected by that. Every statement has a source. The page describes general textbook knowledge and says nothing about any individual person.
In brief
Torasemide is a loop diuretic. It acts not from the blood but from the urine side: there it binds to the Na-K-2Cl co-transporter in the thick ascending part of the loop of Henle and halts its passage.
What this is about
The loop of Henle is a section of the kidney tubule. In its thick ascending part the kidney reclaims a large share of the salts from the filtrate. Four things mesh there:
- The co-transporter NKCC2 in the wall facing the lumen carries sodium, potassium and two chloride into the cell at once. It is driven not by energy of its own but by the sodium gradient that the sodium-potassium pump holds on the blood side.
- A large share of the potassium returns at once to the lumen through the channel ROMK. Without this return path the co-transporter would run out of potassium.
- Because positive charge travels into the lumen continuously in doing so, the lumen is positively charged against the tissue.
- It is precisely this voltage that pushes magnesium and calcium back into the blood between the cells, through pores of claudin-16 and claudin-19.
Torasemide reaches this section not through the blood but through the urine: because it is almost entirely bound to protein in the blood, it is hardly filtered; carriers in the proximal tubule move it actively into the fluid of the tubules. From there it binds to the co-transporter. What is halted is the passage of this one carrier: sodium, potassium and chloride are no longer reclaimed together here and flow onward — and because the voltage in the lumen hangs on that very reclaim, the path of magnesium and calcium between the cells changes as well.
What this means in an individual case depends on many things and belongs in a conversation with a doctor or health practitioner.
Swipe the graphic sideways
The pathway step by step
- Torasemide → In the blood In the blood torasemide hangs almost entirely on proteins. Very little of it therefore passes into the filtrate in the kidney — through the filter alone the substance would hardly reach its site of action. Source 7, 8
- In the blood → Proximal tubule carriers for acids Instead, carriers for organic acids move the substance actively out of the blood into the fluid of the kidney tubules. The label names this secretion as the main route by which torasemide gets into the urine. Source 7, 8
- Proximal tubule → In the tubular urine With the urine torasemide flows on into the loop of Henle. It acts from inside, out of the lumen of the tubule; the label describes exactly this site of action. Source 1, 8
- Urine in the loop → Drawn into the cell NKCC2 The co-transporter draws the three kinds of ion into the cell together. It needs no energy of its own: it is driven by the sodium gradient that the sodium-potassium pump maintains on the blood side. Source 1, 6
- Drawn into the cell → Sodium to the blood Na-K pump · ATP, magnesium On the blood side the sodium-potassium pump moves sodium out of the cell by splitting ATP; chloride leaves there through channels of its own. The gradient on which the co-transporter lives is thus kept up. Source 1, 5
- Drawn into the cell → Potassium to the lumen ROMK A large share of the potassium drawn in returns at once to the lumen through the channel ROMK. Without this return path the co-transporter would run out of potassium, for the urine holds far less of it than of sodium. Source 1, 4
- Potassium to the lumen → Lumen-positive voltage Because positive charge travels back into the lumen continuously, a voltage arises between lumen and blood side: the lumen is positively charged against the tissue. Source 1, 2
- Lumen-positive voltage → Magnesium and calcium claudin-16 and -19 This voltage pushes magnesium and calcium back into the blood between the cells. The passage for it is formed by the proteins claudin-16 and claudin-19. Where the voltage is absent, this path is absent too. Source 2, 3
What the co-transporter reclaims
- Sodium — The co-transporter draws sodium out of the urine into the cell; with it occupied, this reclaim does not happen Source 1, 8
- Potassium — Rides along in the co-transporter and returns to the lumen through ROMK; both hang on the same cycle Source 1, 4
- Chloride — Two chloride ions ride into the cell at each cycle of the co-transporter Source 1, 8
- Magnesium — Is reclaimed between the cells of the loop, pushed by the lumen-positive voltage Source 2, 3
- Calcium — Takes the same path between the cells as magnesium, through the pores of claudin-16 and claudin-19 Source 2
What takes part in these steps
- ATP — Energy source of the sodium-potassium pump on the blood side, which keeps the gradient for the co-transporter Source 5
What the prescribing information states
Trials in the United States with 564 participants on torasemide and 274 on placebo. The prescribing information carries no per-reaction frequency table here; it names only the few comparative figures below. A column for an active comparator is likewise absent — at this place the prescribing information carries no third group.
How to read the table: what matters is the comparison within the row, not the single figure. Three points belong with it — the first row is the only single reaction for which the prescribing information gives any comparison with placebo at all. The second and third rows are lower on torasemide than on placebo. And the third row comes from another part of the same section, from controlled trials in the United States over six weeks; the prescribing information does not name their participant count there, so the column header does not fit that row exactly.
| Torasemide (564) | Placebo (274) | |
|---|---|---|
| Excessive urination | 6.7% | 2.2% |
| Stopped because of adverse events | 3.5% | 4.4% |
| Low potassium value in the laboratory | 1.5% | 3% |
Further reactions have been reported after approval. The prescribing information notes that neither a frequency nor a causal relationship can be derived from such reports; they are therefore not listed here.
Sources
- Mount DB. Thick ascending limb of the loop of Henle. Clin J Am Soc Nephrol 2014 · PubMed 25318757
- Alexander RT, Dimke H. Molecular mechanisms underlying paracellular calcium and magnesium reabsorption in the proximal tubule and thick ascending limb. Ann N Y Acad Sci 2022 · PubMed 36200584
- de Baaij JHF. Magnesium reabsorption in the kidney. Am J Physiol Renal Physiol 2023 · PubMed 36633869
- Palmer BF. Regulation of Potassium Homeostasis. Clin J Am Soc Nephrol 2015 · PubMed 24721891
- Clausen MV, Hilbers F, Poulsen H. The Structure and Function of the Na,K-ATPase Isoforms in Health and Disease. Front Physiol 2017 · PubMed 28634454
- Maskey D, Granados Pineda J, Ortiz PA. Update on NKCC2 regulation in the thick ascending limb (TAL) by membrane trafficking, phosphorylation, and protein-protein interactions. Front Physiol 2024 · PubMed 39717823
- Sherazi AW, Zamir A, Rehman AU et al. A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. Ther Drug Monit 2024 · PubMed 38176856
- US prescribing information (United States): Torsemide Tablets, DailyMed, version of 2 April 2026, sections 11 Description, 12.1 Mechanism of Action and 12.3 Pharmacokinetics · Prescribing information
- US prescribing information (United States): Torsemide Tablets, DailyMed, version of 2 April 2026, sections 6.1 Clinical Trials Experience and 6.2 Postmarketing Experience · Prescribing information
As of 2026-09-25. Draft, written by Claude to schema v2; sources checked in PubMed; expert approval pending
Legal notice
Privacy policy
All biomarkers